NCT00003245View on ClinicalTrials.gov

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 18, 1998

Primary Completion Date

July 30, 2004

Study Completion Date

July 30, 2004

Conditions
Lymphoma
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003245 - Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter